Oral Estradiol and Autoimmune Disease: What Clinicians and Patients Need to Know

What the oral estradiol label says

Oral estradiol tablets are approved for menopausal vasomotor symptoms, vulvovaginal atrophy, hypoestrogenism, osteoporosis prevention and palliative treatment of some advanced breast and prostate cancers [1]. Contraindications include undiagnosed abnormal genital bleeding, breast cancer or its history, estrogen-dependent neoplasia, active or past DVT or PE, active or recent arterial thromboembolic disease, liver dysfunction, hypersensitivity and pregnancy [1]. No autoimmune condition is on that list.

The oral label does not name lupus or any other autoimmune condition in its warnings either, so it offers no lupus-specific guidance. The Climara patch label separately lists protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders, as contraindications [3].

Clot risk: what the route comparisons show

ESTHER, a French case-control study, compared 271 women aged 45 to 70 with a first idiopathic VTE and 610 matched controls. The adjusted odds ratio for VTE in current users versus nonusers was 4.2 (95% CI 1.5 to 11.6) for oral estrogen and 0.9 (0.4 to 2.1) for transdermal [4]. A meta-analysis of eight observational studies and nine randomized trials found pooled odds ratios of 2.5 (1.9 to 3.4) for oral estrogen and 1.2 (0.9 to 1.7) for transdermal, with oral risk highest in the first year at 4.0 (2.9 to 5.7) [2]. The route-specific pooled estimates came from observational studies; the review also included randomized trials [2]. These data are not randomized comparisons of routes.

Boxed warning wording

The oral estradiol tablet label uses the older boxed warning format, with headings on increased endometrial cancer risk and on cardiovascular and other risks [1]. The Women's Health Initiative findings cited in it came from oral conjugated estrogens 0.625 mg, with or without medroxyprogesterone, not from estradiol [1]. The Climara patch label says the relevance of those findings to lower doses, other routes of administration or other estrogen-alone products is not known [3].